gefitinib has been researched along with yuanhuadine in 2 studies
Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (yuanhuadine) | Trials (yuanhuadine) | Recent Studies (post-2010) (yuanhuadine) |
---|---|---|---|---|---|
5,231 | 566 | 2,919 | 10 | 0 | 5 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chung, HJ; Hong, JY; Lee, HJ; Lee, SK; Park, HJ | 1 |
Bach, DH; Fan, YH; Hong, JY; Kim, D; Lee, SK; Luu, TT; Park, HJ | 1 |
2 other study(ies) available for gefitinib and yuanhuadine
Article | Year |
---|---|
Growth inhibition of human lung cancer cells via down-regulation of epidermal growth factor receptor signaling by yuanhuadine, a daphnane diterpene from Daphne genkwa.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Daphne; Disease Models, Animal; Diterpenes; Down-Regulation; ErbB Receptors; Female; Flowers; Humans; Mice; Mice, Nude; Molecular Structure; Terpenes | 2011 |
AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells.
Topics: Acrylamides; Aniline Compounds; Animals; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drugs, Chinese Herbal; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Lung Neoplasms; Male; Mice, Nude; Protein Kinase Inhibitors; Proteolysis; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Signal Transduction; Terpenes; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |